Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases.
Down syndrome
acute lymphoblastic leukemia
acute myeloid leukemia
multi-omics approach
personalized medicine
single-cell RNA sequencing
trisomy 21
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Oct 2023
18 Oct 2023
Historique:
received:
22
09
2023
revised:
10
10
2023
accepted:
12
10
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
The molecular basis of Down syndrome (DS) predisposition to leukemia is not fully understood but involves various factors such as chromosomal abnormalities, oncogenic mutations, epigenetic alterations, and changes in selection dynamics. Myeloid leukemia associated with DS (ML-DS) is preceded by a preleukemic phase called transient abnormal myelopoiesis driven by
Identifiants
pubmed: 37895004
pii: ijms242015325
doi: 10.3390/ijms242015325
pmc: PMC10607483
pii:
doi:
Substances chimiques
Janus Kinases
EC 2.7.10.2
STAT Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero della Salute
ID : Ricerca corrente
Références
Hum Pathol. 2014 May;45(5):1003-9
pubmed: 24746204
Blood. 2010 Feb 4;115(5):1006-17
pubmed: 19965641
Blood. 2004 Sep 1;104(5):1588-9
pubmed: 15317736
Leukemia. 2019 Apr;33(4):893-904
pubmed: 30487598
Cancer Epidemiol. 2018 Dec;57:68-73
pubmed: 30326394
Science. 2021 Jul 9;373(6551):
pubmed: 34244384
Nat Cancer. 2021 Aug;2(8):835-852
pubmed: 34734190
Lancet. 2008 Oct 25;372(9648):1484-92
pubmed: 18805579
Pediatr Blood Cancer. 2005 Jan;44(1):8-12
pubmed: 15390275
Blood. 2014 Jan 2;123(1):70-7
pubmed: 24222333
Oncogene. 2021 Jan;40(4):746-762
pubmed: 33247204
Blood. 2014 Jan 2;123(1):35-40
pubmed: 24235135
Lancet Oncol. 2001 Jul;2(7):429-36
pubmed: 11905737
Nat Rev Genet. 2017 Mar;18(3):147-163
pubmed: 28029161
Leukemia. 2020 Aug;34(8):1984-1999
pubmed: 32433508
Nat Genet. 2013 Nov;45(11):1293-9
pubmed: 24056718
Expert Rev Mol Med. 2021 Apr 27;23:e5
pubmed: 33902785
Blood. 1998 Jan 15;91(2):608-15
pubmed: 9427716
Cancer Cell. 2019 Sep 16;36(3):340
pubmed: 31526763
Nat Genet. 2005 Jun;37(6):613-9
pubmed: 15895080
Leukemia. 2015 Jan;29(1):232-3
pubmed: 25179734
Cancer Lett. 2018 Sep 28;432:69-74
pubmed: 29879498
Medicine (Baltimore). 2021 Oct 8;100(40):e27459
pubmed: 34622870
Blood. 2011 Dec 22;118(26):6752-9; quiz 6996
pubmed: 21849481
Blood. 2003 Jun 1;101(11):4301-4
pubmed: 12586620
Crit Rev Oncog. 2011;16(1-2):25-36
pubmed: 22150305
Biochem Pharmacol. 2022 Jul;201:115046
pubmed: 35483417
Blood. 2013 Dec 5;122(24):3908-17
pubmed: 24021668
Blood. 2009 Jan 15;113(3):646-8
pubmed: 18927438
Nat Rev Dis Primers. 2020 Feb 6;6(1):9
pubmed: 32029743
Nat Genet. 2009 Nov;41(11):1243-6
pubmed: 19838194
Expert Rev Hematol. 2014 Dec;7(6):831-40
pubmed: 25231553
Lancet. 2000 Jan 15;355(9199):165-9
pubmed: 10675114
Am J Med Genet Suppl. 1990;7:262-6
pubmed: 2149959
J Exp Clin Cancer Res. 2023 Oct 6;42(1):259
pubmed: 37803464
Sci Rep. 2020 Jul 31;10(1):12991
pubmed: 32737409
J Biomed Sci. 2021 Apr 12;28(1):27
pubmed: 33840388
Nat Genet. 2002 Sep;32(1):148-52
pubmed: 12172547
Br J Haematol. 2009 Mar;144(6):930-2
pubmed: 19120350
Blood. 2008 Feb 1;111(3):1575-83
pubmed: 17971484
Nature. 2021 Oct;598(7880):327-331
pubmed: 34588693
Leuk Lymphoma. 2021 Sep;62(9):2276-2279
pubmed: 33783296
Nat Commun. 2014 Aug 08;5:4654
pubmed: 25105841
Leukemia. 2016 Sep;30(9):1816-23
pubmed: 27285583
Blood. 2022 Sep 15;140(11):1200-1228
pubmed: 35767897